Clinical Trials Logo

Filter by:
NCT ID: NCT05734794 Recruiting - Clinical trials for Nephrotic Syndrome in Children

Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial

STORM
Start date: February 9, 2023
Phase: Phase 3
Study type: Interventional

The main objective is to evaluate the effectiveness of Rituximab monotherapy versus steroid therapy on children with new-onset nephrotic syndrome within the 52-week follow-up.

NCT ID: NCT05734781 Recruiting - Terminally Ill Clinical Trials

End-of-life Communication From a Chinese Perspective

Start date: May 4, 2023
Phase:
Study type: Observational

The goal of this observational study is to explore experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers. The main question it aims to answer is: • What are the experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers? Participants will be invited to either semi-structured in-depth interviews or focus group discussions to share their thoughts.

NCT ID: NCT05733338 Recruiting - Clinical trials for Acute Mountain Sickness

The Effects of Intermittent Hypoxia on Acute Hypoxic Injury

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This study intends to further reveal the effectiveness of intermittent hypoxia in preventing acute hypoxic injury.

NCT ID: NCT05733208 Recruiting - Myocardial Injury Clinical Trials

The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery

Start date: May 6, 2023
Phase: N/A
Study type: Interventional

This is a multicentre, parallel-group, randomised, sham-controlled, observer blinded trial, assessing the efficacy of remote ischemic preconditioning on preventing myocardial injury after noncardiac surgery.

NCT ID: NCT05733195 Recruiting - Clinical trials for Gestational Diabetes Mellitus

The Study of Biomarker in Early Diagnosis of GDM by Metabolomics

GDM
Start date: May 4, 2022
Phase:
Study type: Observational

Gestational Diabetes Mellitus (GDM) refers to abnormal glucose metabolism during pregnancy, in which elevated blood glucose is first found during pregnancy and meets the criteria for diabetes. In recent years, with the increase of obese women of childbearing age, the incidence of GDM has been rising, the current global average incidence is about 14%, and the incidence in China has increased from 2% in 1999 to 5%-8% at present. If one-step diagnosis is used, the rate will be between 13%-17%, which will greatly increase the social burden. Gestational diabetes mellitus (GDM) significantly increases the risk of diseases for pregnant women and infants, such as abortion and premature delivery, concurrent hypertension, concurrent infection, metabolic disorders, postpartum diabetes, macrosomia, fetal malformation, neonatal hypoglycemia, neonatal respiratory distress syndrome, and so on. It is one of the important public health problems threatening human health. Therefore, the accurate diagnosis of GDM is of great clinical significance for the timely formulation of intervention and treatment measures, reducing the risk of maternal and infant diseases and improving the level of public health.

NCT ID: NCT05732948 Recruiting - Prostate Cancer Clinical Trials

PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

Start date: August 2, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I study which will test the safety of different doses of the patients own immune cells which have been changed to help recognize and destroy the cancer cells. The investigators want to find out what effects, good and/or bad, it has on the body and on the prostate cancer. The immune cells (T cells) used in this study will be the patients own immune cells. They will be removed from the patients blood, changed in the laboratory, and then put back into their body. T cells help the body fight infections. These cells may also kill cancer cells in some cases. Right now the patients T cells are unable to kill the cancer cells. For this reason, the physician will change the T cells by putting in a gene so that they may be able to better recognize and kill the prostate cancer cells. A gene is a portion of information which comes from the DNA and tells the cell what to do. This gene will be put into the patients T cells by a weakened virus. It is hoped that this approach will help the T cells recognize the prostate cancer tumor cells and possibly kill them. This is an entirely new treatment for prostate cancer and it is not known if it will have any beneficial or unexpected harmful effects.

NCT ID: NCT05732467 Recruiting - Amblyopia Clinical Trials

Effectiveness of Virtual Reality Training in Amblyopia

Start date: November 14, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of visual function training software (model: SJ-JRS2021) in the treatment of mild to moderate amblyopia in children. The main questions it aims to answer are: - Whether virtual reality training is more effective than occlusion therapy - Safety of virtual reality training in amblyopia treatment If participants have refractive problems, correct the refraction first and wear corrective glasses. The experimental group will be treated using visual function training therapy software (model: SJ-JRS2021). The control group will be treated with occlusion therapy covering the contralateral eye for 2 hours a day. Researchers will compare experimental group with control group to see if the experimental group has better corrected vision recovery.

NCT ID: NCT05732116 Recruiting - COVID-19 Clinical Trials

PTSD of Surgeons or Anesthesiologists on Prognosis of Surgical Patients

Start date: February 21, 2023
Phase:
Study type: Observational

The objective of this prospective cohort study is to explore the association between the development of post-traumatic stress disorder (PTSD) in surgeons and anesthesiologists and postoperative prognosis in surgical patients they care for during the COVID-19 pandemic. There are 2 cohorts included in this study. The first cohort consists of registered surgeons and anesthesiologists in the study center. The development of PTSD will be evaluated with a series of questionnaires and scales. This cohort defines exposure (with PTSD). The second cohort consists of surgical patients managed by the surgeons and anesthesiologists in the first cohort. The postoperative outcome of these patients will be evaluated thus to explore the association between PTSD in physicians and adverse patient outcomes. The second cohort defines the outcomes( response).

NCT ID: NCT05732077 Recruiting - Clinical trials for Renal Artery Stenosis Atherosclerotic

Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting

FAIR-Pilot
Start date: January 31, 2023
Phase: N/A
Study type: Interventional

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. The goal of this clinical trial is to learn whether Fraction Flow Reserve (FFR) is appropriate to determine stenting in hypertension patients with atherosclerosis renal artery stenosis. The main questions it aims to answer are: - Is it appropriate to use FFR to determine whether or not stenting for hypertension patients with atherosclerosis renal artery stenosis? - To provide detailed data supporting design of further trial, such as sample size calculating, cut-off value for FFR in renal artery stenosis, etc. Participants met the inclusive/exclusive criteria will be randomized to stenting or not in the renal artery, then hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, randomization will be applied. If FFR is <0.80, randomization will be ignored, and stenting will be performed as planned. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.

NCT ID: NCT05732064 Recruiting - Breast Cancer Clinical Trials

Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality

Start date: May 22, 2023
Phase: Phase 4
Study type: Interventional

Breast cancer patients often have sleep disturbances during the perioperative period. Dexmedetomidine is a highly selective alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effects. Previous studies showed that night-time low-dose dexmedetomidine infusion improved sleep quality. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that low-dose dexmedetomidine-esketamine combined nasal administration at night can improve perioperative sleep quality in patients scheduled for breast cancer surgery.